Xocova is Preferred Over Paxlovid for Post-Exposure Prophylaxis Because Paxlovid Failed Its Post-Exposure Prophylaxis Trial
Xocova (ensitrelvir) is FDA-approved specifically for post-exposure prophylaxis of COVID-19, while Paxlovid explicitly failed to demonstrate efficacy for this indication and is not approved for post-exposure prophylaxis. 1, 2
The Evidence is Clear and Definitive
Paxlovid Failed Its Post-Exposure Prophylaxis Trial
The FDA label for Paxlovid explicitly states: "PAXLOVID is not indicated for the post-exposure prophylaxis of COVID-19." 2 In the post-exposure prophylaxis trial, Paxlovid was tested in 2,736 asymptomatic household contacts at both 5-day and 10-day regimens. The primary endpoint was not met—there was no statistically significant reduction in symptomatic SARS-CoV-2 infection compared to placebo:
- 5-day Paxlovid: 2.6% infection rate (risk reduction 29.8%, 95% CI -16.7 to 57.8; P = 0.17)
- 10-day Paxlovid: 2.4% infection rate (risk reduction 35.5%, 95% CI -11.5 to 62.7; P = 0.12)
- Placebo: 3.9% infection rate
This negative trial was published in the New England Journal of Medicine in 2024, confirming that nirmatrelvir-ritonavir does not significantly reduce the risk of symptomatic SARS-CoV-2 infection when used as post-exposure prophylaxis. 3
Xocova Succeeded in Its Post-Exposure Prophylaxis Trial
In stark contrast, Xocova demonstrated a 67% relative risk reduction in preventing COVID-19 in household contacts when administered within 72 hours of symptom onset in the index patient. 4 The SCORPIO-PEP trial showed:
- Ensitrelvir group: 2.9% developed COVID-19
- Placebo group: 9.0% developed COVID-19
- Risk ratio: 0.33 (95% CI 0.22 to 0.49; P < 0.001)
This represents an absolute risk reduction of 6.1 percentage points—a clinically meaningful and statistically significant benefit. 4 Based on this evidence, Xocova received FDA approval specifically for post-exposure prophylaxis in adults and adolescents 12 years and older following contact with an individual who has COVID-19. 1
Practical Implications
When to Use Xocova for Post-Exposure Prophylaxis
- Indication: Household contacts of COVID-19 patients who test negative for SARS-CoV-2
- Timing: Within 72 hours of symptom onset in the index patient (71.1% of trial participants were enrolled within 48 hours) 4
- Dosing: 375 mg on day 1, then 125 mg daily on days 2-5 4
- Efficacy: Works regardless of vaccination status or risk factors for severe disease 4
Why Paxlovid Should Not Be Used for Post-Exposure Prophylaxis
Beyond the failed efficacy trial, Paxlovid has significant practical limitations that make it unsuitable for prophylactic use:
- Extensive drug-drug interactions through ritonavir's CYP3A4 inhibition, requiring careful medication review and potential dose adjustments or discontinuations 5, 6
- Twice-daily dosing for 5-10 days increases pill burden and ritonavir exposure 5
- No proven benefit in the post-exposure prophylaxis setting despite testing both 5-day and 10-day regimens 2, 3
Important Caveats
Paxlovid remains the preferred treatment for established COVID-19 infection in high-risk patients when started within 5 days of symptom onset, with strong evidence for reducing hospitalization (strong recommendation from WHO guidelines). 5 The distinction is critical:
- Treatment of active COVID-19: Use Paxlovid (strong evidence for benefit) 5
- Post-exposure prophylaxis: Use Xocova (only agent with proven efficacy and FDA approval for this indication) 1, 4
The safety profile of Xocova in the post-exposure prophylaxis trial was favorable, with adverse event rates similar to placebo (15.1% vs 15.5%) and no COVID-19-related hospitalizations or deaths. 4